Raf1 Kinase Inhibitor I-CAS 220904-83-6-Calbiochem

C₁₅H₈Br₂INO₂

520.94

MFCD03453076

A potent, cell-permeable, reversible, and ATP-competitive cRAF1 kinase inhibitor (IC₅₀ = 9 nM). Shows ≥100-fold selectivity for Raf kinase versus Cdk1, Cdk2, c-Src, ERK2, MEK, p38, Tie2, VEGFR2, and c-Fms. Predicted broad spectrum antitumor agents. A 10 mM (500 µg/96 µl) solution of Raf1 Inhibitor I (Cat. No. 553003) in DMSO is also available.
A potent, cell-permeable, reversible, and ATP-competitive cRaf1 kinase inhibitor (IC₅₀ = 9 nM). Shows ≥100-fold selectivity for Raf kinase versus Cdk1, Cdk2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms. cRaf1 inhibitors are predicted to be broad spectrum antitumor agents.

Cell permeable: yes
Primary Target
CRAFI kinase
Product competes with ATP.
Reversible: yes

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.







From Catalog:

Desc. Field- added "Predicted broad spectrum antitumor agents."

Lackey, K., et al. 2000. Bioorg. Med. Chem. Lett.10, 223.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

100

≥97% (HPLC)

solid

9 nM IC₅₀

Calbiochem^®

OK to freeze
protect from light

dark orange

DMSO: 200 mg/mL

ambient

−20℃

1 mg in Plastic ampoule
Packaged under inert gas

11 - Combustible Solids

WGK 3